Anti-human CTLA-4 (Ipilimumab Biosimilar)

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Ipilimumab, making it well-suited for research applications. It specifically binds to human CTLA-4 (cytotoxic T lymphocyte antigen-4), also known as CD152—a 33 kDa cell surface receptor encoded by the CTLA4 gene and a member of the CD28 family within the immunoglobulin superfamily. CTLA-4 is expressed on activated T and B lymphocytes and shares structural similarity with the co-stimulatory protein CD28. Both CTLA-4 and CD28 interact with B7 family ligands, B7-1 (CD80) and B7-2 (CD86). However, unlike CD28, CTLA-4 delivers an inhibitory signal upon ligand binding, downregulating T-cell activation and contributing to immune tolerance, thymocyte development, and regulation of immune responses. CTLA-4 is a key immune checkpoint receptor targeted in cancer immunotherapy. Ipilimumab blocks CTLA-4, lifting the inhibitory signal and enabling cytotoxic T cells to mount an effective anti-tumor response.

Specifications

Product name: Anti-human CTLA-4 (Ipilimumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894725

Molecular Weight: 150 kDa